For patients who received anti-HER2 therapy (Fig. 1C, D), those who had ER-negative tumours showed a significantly higher pCR rate than those who had ER-positive tumours in Group 1 (p = 0.01). This evidence concerns the gene ERBB2 and neoplasm.